CBL’s driver status in stage II melanoma faces a variant-level challenge
The genomic case for CBL in stage II melanoma has now met an equally important test: how firmly the variants themselves can be interpreted. The letter to the editor accepts the value of the underlying melanoma dataset, including the report of 11q23.1-q23.3 deletions as a potential prognostic marker in RAS-mutant disease, but it pushes back on a more ambitious claim — that CBL can already be called a true driver gene in this setting.
The concern is not semantic. In cancer genomics, driver designation carries clinical and biological weight because it implies that an alteration is doing more than appearing in a tumor by chance. A driver should confer selective growth advantage, shape tumor behavior, and recur often enough to rise above the background noise of passenger mutations. The letter argues that the current CBL evidence does not yet clear that bar with enough precision.
Why the hotspot is intriguing but not yet definitive
CBL encodes an E3 ubiquitin ligase that restrains RTK-MAPK signaling, so a disruptive alteration is biologically plausible in melanoma. Loss of this brake could amplify growth-factor signaling and tilt cells toward proliferation, survival, and therapy resistance. The hotspot identified in the RING finger domain at positions 417–418 is therefore not trivial; a recurrent lesion in a functionally important domain is exactly the type of pattern that can point toward oncogenic relevance.
Still, plausibility is not proof. The variants were enriched in the NF1 subtype, but not confined to it, and the letter suggests that the current presentation leaves open whether the signal is truly recurrent or simply assembled from a heterogeneous set of rare changes. Of 24 variants across 20 tumors, 21 were unique. In practical genomic terms, rarity weakens the claim of recurrence, especially when variant interpretation has to do the heavy lifting for driver nomination.
One sentence matters here: uniqueness is not the same as recurrence.
Variant annotation gaps limit independent review
A central objection concerns the way the variants were reported. Protein-level nomenclature alone, without corresponding cDNA information, makes independent verification harder than it should be. For a gene being positioned as a putative driver, that omission creates an avoidable barrier to replication, cross-database matching, and consistent clinical curation.
The letter also points to the absence of variant allele frequencies. Without those data, it is difficult to judge clonality or sort a true somatic event from a sequencing artifact. That issue becomes sharper in FFPE material, where degradation and technical noise can complicate interpretation. For a gene discovery claim, technical confidence matters because a weak signal can masquerade as a biologic one if variant-level details are sparse.
The coexistence patterns deepen the uncertainty. Several variants overlap with heterozygous deletions, which is at least compatible with loss-of-function biology. One case, however, shows coexistence with an amplification, a configuration that sits uneasily beside the usual expectation for a suppressive or loss-of-function role. In a field where copy-number context can change the meaning of a variant, those mixed genomic states deserve careful scrutiny.
Context-dependent databases cannot substitute for melanoma-specific evidence
The letter also questions the way external annotation resources were used. COSMIC counts were not consistently melanoma-specific, and OncoKB classifications came from evidence generated in other cancers. Those databases are useful, but they do not erase tissue specificity. A variant that is biologically important in one malignancy may be neutral, secondary, or even misleading in another.
This is especially relevant for CBL, where the functional consequences may vary by tumor context. The gene’s role in ubiquitin-mediated signaling and receptor tyrosine kinase regulation makes it attractive as a candidate, yet context determines whether a given alteration behaves as a driver, modifier, or passenger. Melanoma biology, with its distinct mutational architecture and pathway dependencies, should not inherit oncogenicity from another disease site by default.
VUS inflation can distort enrichment signals
The sharpest analytical concern is the possibility that inclusion of variants of uncertain significance may have inflated the enrichment analysis. If variants with unclear pathogenicity are counted alongside more convincing lesions, statistical enrichment can look stronger than the underlying biology deserves. The letter asks a direct question: would the significance of CBL as a driver survive if VUS were excluded from the enrichment calculation?
That question goes to the heart of contemporary cancer genomics. Variant classification is not a side exercise; it is the mechanism by which sequencing data become clinically interpretable. When the line between driver and passenger blurs, the downstream consequences reach diagnosis, prognostication, and eventual therapeutic targeting. A gene can look recurrent in aggregate while still lacking the variant-level evidence needed to justify a driver label.
Functional validation remains the missing step
No designated ClinGen Gene Curation Expert Panel currently exists for CBL, so interpretation relies on broader somatic-variant standards rather than gene-specific consensus. Those standards are essential, but they are not a substitute for experimental proof. Functional assays are still needed to determine whether the observed variants actually alter CBL activity, disrupt RTK-MAPK restraint, or produce a growth advantage in melanoma cells.
Without that evidence, the safest reading is cautious: CBL remains a promising candidate, not an established driver. The genomic pattern is interesting, the hotspot is real, and the pathway biology is credible. Yet the current dataset leaves too many interpretive gaps at the variant level to support a firm driver designation in stage II melanoma.
The next step is not another label. It is functional confirmation, melanoma-specific recurrence, and variant-level clarity before the field treats CBL as more than a candidate.